News - Page 6 of 13 - Leukaemia Care

10th May 2022

Ropeginterferon alpha 2b rejected and will not be available in Scotland

Charities including Leukaemia Care campaigned for the Scottish Medicines Consortium (SMC) to approve ropeginterferon alpha 2b (brand name of Besremi) on the NHS in Scotland for the treatment of polycthaemia vera (PV) patients.

9th May 2022

Venetoclax with obinutuzumab approved for a wider group of untreated CLL patients in Scotland

Charities including Leukaemia Care successfully campaigned for the Scottish Medicines Consortium (SMC) to approve venetoclax with obinutuzumab on the NHS in Scotland as a first-line treatment for a larger group of chronic lymphocytic leukaemia (CLL) patients.

6th May 2022

Charities including Leukaemia Care successfully campaign for the approval of a new treatment for CLL patients in England

The National Institute for Health and Care Excellence (NICE) have made recommendations for venetoclax monotherapy to become available as an NHS treatment option for chronic lymphocytic leukaemia (CLL) in England.

11th April 2022

Leukaemia Care successfully campaigns for new acute myeloid leukaemia (AML) treatment in Scotland

Exciting news for acute myeloid leukaemia (AML) patients in Scotland. It has been announced that venetoclax with a hypomethylating agent (e.g., azacitidine) will be a treatment option for newly diagnosed AML patients in Scotland who are unsuitable for intensive chemotherapy.

8th April 2022

What is the 10 year Cancer Plan?

To mark World Cancer Day in February this year, Sajid Javid MP, the Secretary of State for Health and Social Care, announced his plan to create a new plan for cancer care in England. Today (Friday 8th April), we have submitted our response to a call for thoughts on what this plan should include.

1st April 2022

Leukaemia Care’s COVID-19 Statement

Our policy team brings you up to speed on our latest response to COVID-19 and how we are sharing the impact it has had on patients with decision makers.

1st April 2022

Leukaemia Care partners with Dalata Hotels in England, Scotland and Wales for the next three years

Dalata Hotel Group announce three new charity partners Marie Keating Foundation, Leukaemia Care and Air Ambulance Northern Ireland all set to benefit over three-year partnership.

16th December 2021

New treatment option for AML patients approved in England, thanks to campaign by Leukaemia Care

The National Institute for Health and Care Excellence (NICE) have made recommendations for venetoclax in combination with azacitidine to become available as an NHS treatment option for acute myeloid leukaemia (AML) in England.

10th December 2021

Leukaemia Care and Lymphoma Action release new patient information booklet on CLL and SLL

Leukaemia Care are pleased to announce our new patient information booklet in collaboration with Lymphoma Action about chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).

17th November 2021

Leukaemia Care and the MPN Voice successfully campaign for patients with myelofibrosis to access new treatment

The National Institute for Health and Care Excellence (NICE) have today made recommendations for fedratinib for myelofibrosis (MF) to become available as an NHS treatment option patients for a period of time in England.